.Merck beats revenues assumptions, increases purchases outlook on solid demand for leading drugs like Keytruda CNBCMerck & Co. (MRK US) Trumps Income Projections as Keytruda Sales Growth BloombergMerck Sell: Pharma Titan Posts Powerful Outcomes, But Outlook Falls Short Capitalist's Service DailyMerck Announces Second-Quarter 2024 Financial Outcomes Yahoo FinanceMerck trumps earnings as well as purchases assumptions surrounded by Keytruda asset, however delivers combined full-year expectation MarketWatch.